Novo Nordisk reported positive mid-stage trial results for Amycretin, showing up to 14.5% weight loss and significant reductions in HbA1c levels in people with type 2 diabetes. The study tested weekly injections and daily oral doses in 448 patients inadequately controlled on metformin, with 40% also using SGLT2 inhibitors.